News + Filings IR Vault
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Inv. presentation
Appointed director
Director departure
Credit agrmnt [a]
Asset disposition
Acq. announced
Appointed CFO
Consulting agrmnt
Auditor change
Notes underwriting agrmnt
Director comp.
Employment agrmnt
Dividend declared
Appointed COO
Filed Chapter 11
Monthly dividend
Preliminary results
Accel. buyback
Cert. of designation
Acq. completed
Monthly oper. report
Merger agrmnt [a]
Quarterly results presentation
Class action filed
CFO resigned
Departure of a VP
SSS news release
Asset acq. complete
Letter to company
Buyback announced
Bonus plan approved
Upcoming conference date
Notes have priced
Coll. bargaining agrmnt
10-Q late filing
RE purchase
Amended bylaws
New credit facility
|
|
All Companies
|
Create: Portfolio | Alert |
All | News | Filings
| Date Filed | Symbol | Type | Description |
| 10/29/2011 |
LPHC
|
8-K
| Filed a monthly operating report |
| 09/07/2011 |
TRMA
|
8-K
| Form 8-K - Current report |
| 07/11/2011 |
TRMA
|
8-K
| Filed a monthly operating report |
| 06/01/2011 |
TRMA
|
8-K
| Form 8-K - Current report |
| 05/12/2011 |
TRMA
|
8-K
| Filed a monthly operating report |
| 04/08/2011 |
TRMA
|
8-K
| Form 8-K - Current report |
| 03/04/2011 |
TRMA
|
8-K
| Filed a monthly operating report |
| 02/02/2011 |
TRMA
|
8-K
| Form 8-K - Current report |
| 01/05/2011 |
TRMA
|
8-K
| Filed a monthly operating report |
| 12/16/2010 |
TRMA
|
8-K
| Filed a monthly operating report |
| 10/25/2010 |
ABPI
|
8-K
| Filed a monthly operating report|
Docs:
|
"Biovest Announces $7 Million Financing Required to Exit from Reorganization and Advance Key Regulatory and Commercial Strategies for BiovaxID ® Cancer Vaccine TAMPA, FL and MINNEAPOLIS, MN - October 25, 2010 - Biovest International, Inc. today announced that the Company has entered into definitive loan documents and other agreements for the issuance of $7 million of convertible debtor-in-possession term notes and common stock purchase warrants to institutional investors. ROTH Capital Partners, LLC acted as the exclusive placement agent. The closing occurred on October 19 th , 2010, subject to the Court entering a final order approving the transaction. On October 25, 2010, the Court entered a Final Order approving this financing transaction. Biovest intends to use the proceeds from the DIP ...",
"Monthly Operating Report of Accentia Biopharmaceuticals, Inc. for the period September 1, 2010 through September 30, 2010 filed in the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17795-KRM Document No. 1396" |
|
| 10/25/2010 |
BVTI
|
8-K
| Filed a monthly operating report|
Docs:
|
"Securities Purchase Agreement, (the “Securities Purchase Agreement”), among Biovest International, Inc. (the “Company”) and the investors listed on the Schedule of Buyers attached thereto (the “Buyers”)",
"Form of Debtor in Possession Secured Convertible Note issued October 19, 2010",
"Form of Series A Warrant issued October 19, 2010",
"Form of Series B Warrant issued October 19, 2010",
"Interim Order of the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17796-KRM",
"Final Order of the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17796-KRM",
"Biovest Announces $7 Million Financing Required to Exit from Reorganization and Advance Key Regulatory and Commercial Strategies for BiovaxID® Cancer Vaccine TAMPA, FL and MINNEAPOLIS, MN - October 25, 2010 - Biovest International, Inc. today announced that the Company has entered into definitive loan documents and other agreements for the issuance of $7 million of convertible debtor-in-possession term notes and common stock purchase warrants to institutional investors. ROTH Capital Partners, LLC acted as the exclusive placement agent. The closing occurred on October 19 th , 2010, subject to the Court entering a final order approving the transaction. On October 25, 2010, the Court entered a Final Order approving this financing transaction. Biovest intends to use the proceeds from the DIP N...",
"Monthly Operating Report of Biovest International, Inc. for the period September 1, 2010 through September 30, 2010 filed in the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17796-KRM Document No. 56" |
|
| 09/24/2010 |
BVTI
|
8-K
| Form 8-K - Current report |
| 09/24/2010 |
ABPI
|
8-K
| Form 8-K - Current report |
| 08/20/2010 |
BVTI
|
8-K
| Form 8-K - Current report |
| 08/20/2010 |
ABPI
|
8-K
| Form 8-K - Current report |
| 07/26/2010 |
ABPI
|
8-K
| Form 8-K - Current report |
| 07/26/2010 |
BVTI
|
8-K
| Filed a monthly operating report|
Docs:
|
"FDA Grants Orphan Drug Status for Personalized Cancer Vaccine, BiovaxID®, Targeting Mantle Cell Lymphoma TAMPA, FL and MINNEAPOLIS, MN - July 26, 2010 - Biovest International, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BiovaxID®, Biovest's personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma. Mantle cell lymphoma is an aggressive and lethal B-cell blood cancer for which there is no current consensus standard-of-care. Mantle cell lymphoma is the newest disease for which Biovest has announced its intent to pursue regulatory approval for and Orphan Drug Designation represents a significant development step in the Company's regulatory strategy. The FDA previously granted Orphan Drug Designation f...",
"Biovest's Stock Listing Upgraded to OTCQB™ Market TAMPA, FL and MINNEAPOLIS, MN - July 12, 2010 - Biovest International, Inc. , a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company's publicly-traded shares are now being quoted on the newly launched OTCQB™ Market. The upgraded stock listing is a direct result of Biovest filing its Annual Reports and its Quarterly Reports with the Securities and Exchange Commission , as the Company advances plans to emerge from reorganization. Launched in April 2010, the OTCQB is a new market tier for OTC-traded U.S. companies that are registered and reporting with the SEC. Signaling its plans to emerge from Chapter 11 as a fully reorganized public company, Biovest also announced...",
"Monthly Operating Report of Biovest International, Inc. for the period June 1, 2010 through June 30, 2010 filed in the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17796-KRM Document No. 53" |
|
| 06/25/2010 |
ABPI
|
8-K
| Filed a monthly operating report |
| 06/25/2010 |
BVTI
|
8-K
| Filed a monthly operating report |
| 05/26/2010 |
BVTI
|
8-K
| Form 8-K - Current report |
| 05/26/2010 |
ABPI
|
8-K
| Filed a monthly operating report |
| 04/26/2010 |
BVTI
|
8-K
| Filed a monthly operating report |
| 04/26/2010 |
ABPI
|
8-K
| Filed a monthly operating report |
| 03/23/2010 |
BVTI
|
8-K
| Form 8-K - Current report |
| 03/23/2010 |
ABPI
|
8-K
| Form 8-K - Current report |
| 02/22/2010 |
BVTI
|
8-K
| Form 8-K - Current report |
| 02/22/2010 |
ABPI
|
8-K
| Form 8-K - Current report |
| 01/20/2010 |
BVTI
|
8-K
| Filed a monthly operating report |
| 01/20/2010 |
ABPI
|
8-K
| Form 8-K - Current report |
| 12/22/2009 |
BVTI
|
8-K
| Filed a monthly operating report |
| 12/22/2009 |
ABPI
|
8-K
| Filed a monthly operating report |
| 12/01/2009 |
BVTI
|
8-K
| Form 8-K - Current report |
| 12/01/2009 |
ABPI
|
8-K
| Form 8-K - Current report |
|
|
|